Junction & GRAIL Partner to Streamline Galleri Multi-Cancer Test Access Across Digital Health Platforms

Through the collaboration, Junction will support healthcare organizations in embedding Galleri into patient care pathways using its unified ordering and diagnostic operations platform.

Junction, an NY-based healthtech startup, has partnered with GRAIL, a CA-based biotech startup, to expand access to the Galleri multi-cancer early detection test by enabling digital health companies and healthcare organizations to integrate the test directly into their clinical and operational workflows through Junction’s diagnostic infrastructure platform.

The Galleri blood test, developed by GRAIL, is designed to detect a shared cancer signal across more than 50 cancer types, including many that currently lack standard screening recommendations.

Through the collaboration, Junction will support healthcare organizations in embedding Galleri into patient care pathways using its unified ordering and diagnostic operations platform.

The company’s infrastructure includes integrated test ordering, physician network support, and workflow management capabilities intended to reduce the administrative and logistical burden associated with offering advanced diagnostics at scale.

“As demand for proactive and preventative care grows, platforms need reliable infrastructure to operationalize advanced diagnostics at scale,” said Maitham Dib, Junction’s Founder. “Our collaboration with GRAIL helps bring Galleri into real-world care models more efficiently.”

For GRAIL, the collaboration reflects a broader strategy to increase adoption of the Galleri test by reducing operational barriers for providers and healthcare platforms seeking to incorporate multi-cancer early detection into care delivery.

“Single-cancer screenings are an important tool for detection and diagnosis of five cancers in the U.S, but 70% of cancer deaths are caused by cancers without recommended screening tests. GRAIL is excited to collaborate with Junction to broaden access to the Galleri multi-cancer early detection test through a streamlined experience for healthcare organizations and prescribing providers,” said Megan Hall, PhD, vice president of Medical Affairs at GRAIL.

“Junction’s infrastructure helps simplify the operational steps around offering Galleri, making it easier for providers to integrate the test into care delivery.”

The partnership is expected to allow organizations using Junction’s platform to order the Galleri test directly, support clinical operations across multiple states, manage testing workflows more efficiently, and improve coordination between patients and providers. The infrastructure also includes physician follow-up support for patients receiving the test.

Stay tuned for more such updates on Digital Health News